ALNEVNeovacsALNEV info
$1.18info-6.60%24h
Global rank3098
Market cap$4.15B
Change 7d-25.15%
YTD Performance565000.00%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Neovacs (ALNEV) Stock Overview

    Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.

    ALNEV Stock Information

    Symbol
    ALNEV
    Address
    3-5, Impasse ReilleParis, 75014France
    Founded
    -
    Trading hours
    -
    Website
    https://www.neovacs.com
    Country
    🇫🇷 France
    Phone Number

    Neovacs (ALNEV) Price Chart

    -
    Value:-

    Neovacs Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.18
    N/A
    Market Cap
    $4.15B
    N/A
    Shares Outstanding
    3.52B
    N/A
    Employees
    23.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org